Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard-dose versus low-dose Avastin for neovascular age-related macular degeneration
2009-014280-38Phase 4Terminated
- Sponsor
- Nottingham University Hospitals
- Start
- Aug 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of bevacizumab in exudative macular degeneration (2 arms), sponsored by Nottingham University Hospitals. Primary endpoint: Time to vision deterioration. Started Aug 2010; status: terminated.
02
Drugs
bevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2009-014280-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014280-38.